U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06928246) titled 'The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis' on April 07.
Brief Summary: The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
Study Start Date: July 01, 2025
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
DRUG: Onabotulinum Toxin Type A - Phase 1b
The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.
DRUG: Onabotulinum Toxin...